18P - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes
Autor: | Vitiello, P.P., Cardone, C., Ciardiello, D., Belli, V., Matrone, N., Borrelli, C., Poliero, L., De Falco, V., Giunta, E.F., Vitale, P., Zanaletti, N., Tirino, G., Troiani, T., Ciardiello, F., Martinelli, E. |
---|---|
Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
Databáze: | ScienceDirect |
Externí odkaz: |